BRII-B (02137) surged over 8% during intraday trading. As of press time, the stock was up 4.63%, trading at HK$2.26 with a turnover of HK$25.34 million.

Guotai Junan Securities released a research report stating that BRII-B focuses on infectious diseases and central nervous system disorders, advancing a pipeline that encompasses multiple unique drug candidates. The firm noted that BRII-B is set to achieve several milestones related to Elebsiran in the near term: In the first half of 2025, the ENSURE study Cohort 4 will present 48-week end-of-treatment data at EASL 2025; ENSURE study Cohorts 1-3 will present 24-week follow-up data at EASL 2025; ENSURE study Cohort 4 will release 24-week follow-up data; and the ENRICH study will present end-of-treatment data.